BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 15542506)

  • 1. What is the best management strategy for high grade dysplasia in Barrett's oesophagus? A cost effectiveness analysis.
    Shaheen NJ; Inadomi JM; Overholt BF; Sharma P
    Gut; 2004 Dec; 53(12):1736-44. PubMed ID: 15542506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett's esophagus.
    Das A; Wells C; Kim HJ; Fleischer DE; Crowell MD; Sharma VK
    Endoscopy; 2009 May; 41(5):400-8. PubMed ID: 19418393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost effectiveness of radiofrequency ablation for Barrett's esophagus.
    Hur C; Choi SE; Rubenstein JH; Kong CY; Nishioka NS; Provenzale DT; Inadomi JM
    Gastroenterology; 2012 Sep; 143(3):567-575. PubMed ID: 22626608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-utility analysis of ablative therapy for Barrett's esophagus.
    Inadomi JM; Somsouk M; Madanick RD; Thomas JP; Shaheen NJ
    Gastroenterology; 2009 Jun; 136(7):2101-2114.e1-6. PubMed ID: 19272389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of photodynamic therapy for high-grade dysplasia in Barrett's esophagus.
    Vij R; Triadafilopoulos G; Owens DK; Kunz P; Sanders GD
    Gastrointest Endosc; 2004 Nov; 60(5):739-56. PubMed ID: 15557950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
    Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
    Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endoscopic versus surgical therapy for early cancer in Barrett's esophagus: a decision analysis.
    Pohl H; Sonnenberg A; Strobel S; Eckardt A; Rösch T
    Gastrointest Endosc; 2009 Oct; 70(4):623-31. PubMed ID: 19394011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia.
    Hur C; Nishioka NS; Gazelle GS
    Dig Dis Sci; 2003 Jul; 48(7):1273-83. PubMed ID: 12870783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.
    Provenzale D; Schmitt C; Wong JB
    Am J Gastroenterol; 1999 Aug; 94(8):2043-53. PubMed ID: 10445526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A guide for surveillance of patients with Barrett's esophagus.
    Provenzale D; Kemp JA; Arora S; Wong JB
    Am J Gastroenterol; 1994 May; 89(5):670-80. PubMed ID: 8172136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A UK-based cost-utility analysis of radiofrequency ablation or oesophagectomy for the management of high-grade dysplasia in Barrett's oesophagus.
    Boger PC; Turner D; Roderick P; Patel P
    Aliment Pharmacol Ther; 2010 Dec; 32(11-12):1332-42. PubMed ID: 21050235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analysis of esophagectomy and other techniques in the management of high-grade dysplasia of Barrett's esophagus.
    Deb SJ; Shen KR; Deschamps C
    Dis Esophagus; 2012 May; 25(4):356-66. PubMed ID: 21518102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life in patients with various Barrett's esophagus associated health states.
    Hur C; Wittenberg E; Nishioka NS; Gazelle GS
    Health Qual Life Outcomes; 2006 Aug; 4():45. PubMed ID: 16884539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus.
    Benaglia T; Sharples LD; Fitzgerald RC; Lyratzopoulos G
    Gastroenterology; 2013 Jan; 144(1):62-73.e6. PubMed ID: 23041329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photodynamic therapy for Barrett's esophagus with high-grade dysplasia: a cost-effectiveness analysis.
    Comay D; Blackhouse G; Goeree R; Armstrong D; Marshall JK
    Can J Gastroenterol; 2007 Apr; 21(4):217-22. PubMed ID: 17431509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Barrett's oesophagus: a review of costs of the illness.
    Arguedas MR; Eloubeidi MA
    Pharmacoeconomics; 2001; 19(10):1003-11. PubMed ID: 11735670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive carcinoma after endoscopic ablative therapy for high-grade dysplasia in Barrett's oesophagus.
    van Hillegersberg R; Haringsma J; ten Kate FJ; Tytgat GN; van Lanschot JJ
    Dig Surg; 2003; 20(5):440-4. PubMed ID: 12900536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oesophagectomy remains the gold standard for treatment of high-grade dysplasia in Barrett's oesophagus.
    Sujendran V; Sica G; Warren B; Maynard N
    Eur J Cardiothorac Surg; 2005 Nov; 28(5):763-6. PubMed ID: 16188449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness model of endoscopic screening and surveillance in patients with gastroesophageal reflux disease.
    Gerson LB; Groeneveld PW; Triadafilopoulos G
    Clin Gastroenterol Hepatol; 2004 Oct; 2(10):868-79. PubMed ID: 15476150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling the cost-effectiveness of strategies for treating esophageal adenocarcinoma and high-grade dysplasia.
    Gordon LG; Hirst NG; Mayne GC; Watson DI; Bright T; Cai W; Barbour AP; Smithers BM; Whiteman DC; Eckermann S;
    J Gastrointest Surg; 2012 Aug; 16(8):1451-61. PubMed ID: 22644445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.